Cencora Raises Fiscal 2026 Adjusted Diluted EPS Outlook to at Least $17.90

By Public Technologies
  • Cencora now expects fiscal 2026 adjusted diluted EPS of at least $17.90, versus its previous $17.75-$17.95 range.
  • The revised outlook reflects strength in its U.S. Healthcare Solutions segment.
  • Its planned American Oncology Network acquisition carries a $2.4 billion enterprise value, including up to $100 million in contingent value rights.
  • The acquisition is expected to lift adjusted diluted EPS in the second year following closing.
  • Fiscal 2027 expectations will be discussed on the fiscal fourth-quarter 2026 earnings call on November 4, 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cencora Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202610210730BIZWIRE_USPR_____20261020_BW319270) on October 21, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.